Business
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from Percheron TherapeuticsPercheron Therapeutics aims to commence phase II clinical development of HMBD-002 in CY2026 SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a biotherapeutics company discovering and developing transformat
About this update from Percheron Therapeutics Limited
[{"type":"image","alt":"Hummingbird Bioscience","displaySize":"","headline":null,"caption":"Hummingbird Bioscience","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/b11647fc5ffa1850c9d0e9c9f17c7997"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yJ8r_QfHnNvufo2U4NDXIw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b11647fc5ffa1850c9d0e9c9f17c7997","width":300,"height":120}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical development ","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from Percheron Therapeutics","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"Percheron Therapeutics aims to commence phase II clinical development of HMBD-002 in CY2026","length":91,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":365,"olType":false},{"type":"text","content":"SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it has granted Percheron Therapeutics Limited (ASX: PER) an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002 in all territories and indications. Under the terms of the agreement, Hummingbird Bioscience will be eligible to receive up to USD 290 million in upfront and milestone payments, plus royalties on net sales.","length":542,"tagName":"p"},{"type":"text","content":"HMBD-002 is a monoclonal antibody therapy targeting VISTA, a novel checkpoint involved in the body’s immune response to cancer. HMBD-002 has successfully completed a phase I clinical trial in the United States, under an Investigational New Drug application with the US Food and Drug Administration, which showed the drug to be pharmacologically active and generally safe and well-tolerated. Percheron Therapeutics aims to continue clinical development of HMBD-002 in CY2026.","length":474,"tagName":"p"},{"type":"text","content":"“Given the potential benefits of VISTA blockade in mul...